The purpose of this study is to see if batoclimab is safe and helps people with chronic inflammatory demyelinating polyneuropathy (CIDP), an autoimmune disorder. Batoclimab is also known as IMVT-1401. Batoclimab is injected under the skin (subcutaneously) and targets the immune system.

The purpose of this study is to identify and genomically-characterize individuals with genetically unexplained neurodevelopmental disorders, such as epilepsy. The overarching goal is to provide patients with improved information about the underlying genetic basis of their disorder and illuminate novel genetically-defined treatment approaches in the future.

The objective of the registry is to create a cohort of patients with NMOSD. This registry will be used for future research, as well as improvements to the diagnosis, treatment, and understanding of NMOSD.